This new version of Myrian® brings many clinical innovations and a new application.

Achieving a positive Net Income within this first 2019 semester validates the strategic choices set by the new governance in 2018, generating profits for the first half of 2019 financial year.

Myrian® XP-Mammo, can now be commercialized on the European market.

Myrian® XP Prostate, the new reference tool for worldwide prostate experts.

Elonav, a brand-new application dedicated to specifical needs of neurosurgeons.

Presentation of 3 innovative products based on Myrian® technology.

Strong growth, reaching operating balance.

suspension of the automatic drawdowns of bounds convertible into shares (« OCA »), initially planned in the contract signed on August 27, 2018.

Companies announce today the signing of a pluriannual partnership and distribution agreement

Award ceremony at RSNA 2018 congress